Second Complete Remission of Relapsed Stage IV Non-Small Cell Lung Cancer Following Retreatment
![]() |
Yoo, Su-Jin
(Department of Internal Medicine, Chungnam National University Hospital & Cancer Research Institute, Chungnam National University School of Medicine)
Lee, Jeong-Eun (Department of Internal Medicine, Chungnam National University Hospital & Cancer Research Institute, Chungnam National University School of Medicine) Jung, Sun-Young (Department of Internal Medicine, Chungnam National University Hospital & Cancer Research Institute, Chungnam National University School of Medicine) Park, Dong-Il (Department of Internal Medicine, Chungnam National University Hospital & Cancer Research Institute, Chungnam National University School of Medicine) Park, Myoung-Rin (Department of Internal Medicine, Chungnam National University Hospital & Cancer Research Institute, Chungnam National University School of Medicine) Park, Hee-Sun (Department of Internal Medicine, Chungnam National University Hospital & Cancer Research Institute, Chungnam National University School of Medicine) Jung, Sung-Soo (Department of Internal Medicine, Chungnam National University Hospital & Cancer Research Institute, Chungnam National University School of Medicine) Kim, Ju-Ock (Department of Internal Medicine, Chungnam National University Hospital & Cancer Research Institute, Chungnam National University School of Medicine) Kim, Sun-Young (Department of Internal Medicine, Chungnam National University Hospital & Cancer Research Institute, Chungnam National University School of Medicine) |
1 | DeVita VT, Hellman S, Rosenberg SA. Cancer: principles and practice of oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. |
2 | Lee SY, Park JY. Personalized therapy in lung cancer: focused on molecular targeted therapy. J Lung Cancer 2011;10:1-12. DOI |
3 | Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-9. DOI |
4 | Yokouchi H, Yamazaki K, Kinoshita I, Konishi J, Asahina H, Sukoh N, et al. Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer. BMC Cancer 2007;7: |
5 | National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: small cell lung cancer, v.3. Fort Washington, PA: National Comprehensive Cancer Network; 2011. |
6 | Cara S, Tannock IF. Retreatment of patients with the same chemotherapy: implications for clinical mechanisms of drug resistance. Ann Oncol 2001;12:23-7. |
![]() |